Retail investors buy Novo dip after disappointing weight-loss drug data

By Bhanvi Satija (Reuters) – U.S. retail investor fund flows into Novo Nordisk surged 32-fold on Friday, as the Danish drugmaker’s weaker-than-expected obesity drug data offered a rare dip-buying opportunity, according to Vanda Research. Daily net flows climbed to $15.6 million from $0.49 million a day earlier, after eagerly anticipated data showed Novo’s experimental drug,…

Read More

Ford donates $1 million and fleet of vehicles to Trump’s inauguration

By Nora Eckert and David Shepardson DETROIT (Reuters) – Ford Motor Co is donating $1 million and a fleet of vehicles to U.S. President-elect Donald Trump’s January inauguration, a company spokesperson said on Monday. Policies on tariffs and electric vehicles that are being considered by the incoming administration would likely affect Detroit carmakers like Ford,…

Read More

Lilly’s weight-loss treatment Zepbound becomes first FDA-approved drug for sleep apnea

By Bhanvi Satija (Reuters) -The U.S. Food and Drug Administration on Friday approved Eli Lilly’s weight-loss treatment, Zepbound, for obstructive sleep apnea, making it the first drug greenlighted to directly treat patients with the common sleeping disorder. The regulator approved the drug for moderate to severe obstructive sleep apnea in adults with obesity, the company…

Read More